Clincosm LogoSign in Get a demo

Ovarian Cancer

Showing NaN - NaN of 107
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Genetic Predisposition to Disease, Breast Cancer Female, Ovarian Cancer Trial in Philadelphia (Sequential EHR Communications)

Not yet recruiting
  • Genetic Predisposition to Disease
  • +6 more
  • Sequential EHR Communications
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Feb 8, 2023

Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified

Recruiting
  • Endometrial Cancer
  • +8 more
  • Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
  • Orlando, Florida
  • +21 more
Feb 2, 2023

Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)

Recruiting
  • Advanced Malignancies
  • +4 more
  • Fayetteville, Arkansas
  • +61 more
Jan 10, 2023

OVARIAN CANCER Trial in Worldwide (Cobimetinib, Niraparib, Atezolizumab)

Recruiting
  • OVARIAN CANCER
  • Tucson, Arizona
  • +28 more
Jan 10, 2023

Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))

Completed
Has Results
  • Ovarian Cancer
  • +7 more
  • Enapotamab vedotin (HuMax-AXL-ADC)
  • Phoenix, Arizona
  • +40 more
Dec 12, 2022

Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma Trial in Philadelphia (huCART-meso cells)

Recruiting
  • Lung Adenocarcinoma
  • +5 more
  • huCART-meso cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Dec 1, 2022

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Tumors Trial in Worldwide (Paclitaxel, Carboplatin, Atezolizumab)

Completed
  • Ovarian Cancer
  • +2 more
  • Phoenix, Arizona
  • +267 more
Nov 7, 2022

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Philadelphia (MOv19-BBz CAR T cells, Alpha Folate

Recruiting
  • Ovarian Cancer
  • +2 more
  • MOv19-BBz CAR T cells
  • Alpha Folate Receptor expression test
  • Philadelphia, Pennsylvania
    University of Pennsylvania Health System
Sep 12, 2022

Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

Recruiting
  • Breast Cancer
  • +15 more
  • Goodyear, Arizona
  • +146 more
Aug 24, 2022

Ovarian Cancer, Breast Cancer Trial in Worldwide (Olaparib)

Enrolling by invitation
  • Ovarian Cancer
  • Breast Cancer
  • Boca Raton, Florida
  • +98 more
Aug 22, 2022

Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer Trial in Worldwide (BT5528,

Recruiting
  • Advanced Solid Tumor Historically Known for High EphA2 Expression
  • +6 more
  • Encinitas, California
  • +27 more
Aug 17, 2022

Ovarian Cancer Trial in Washington, Baltimore, Philadelphia (Fostamatinib and Paclitaxel)

Active, not recruiting
  • Ovarian Cancer
  • Fostamatinib and Paclitaxel
  • Washington, District of Columbia
  • +2 more
Aug 10, 2022

Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T

Active, not recruiting
  • Urinary Bladder Cancer
  • +9 more
  • Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
  • Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
  • Miami, Florida
  • +10 more
Aug 9, 2022

Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer Trial in United States (STRO-002, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +4 more
  • Tampa, Florida
  • +5 more
Aug 1, 2022

NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • CART-TnMUC1
  • +2 more
  • Phoenix, Arizona
  • +9 more
Jul 18, 2022

Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,

Recruiting
  • Any Advanced Solid Tumors
  • +6 more
  • Tampa, Florida
  • +7 more
Jul 13, 2022

Advanced Cancer, Metastatic Cancer, Ovarian Cancer Trial in United Kingdom, United States (ART0380, Gemcitabine, Irinotecan)

Recruiting
  • Advanced Cancer
  • +4 more
  • Denver, Colorado
  • +10 more
Jul 6, 2022

Ovarian Cancer Trial in Philadelphia (OTL38, intraoperative imaging camera system)

Withdrawn
  • Ovarian Cancer
  • OTL38
  • intraoperative imaging camera system
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jun 23, 2022

Ovarian Cancer, Fatigue, Coping Behavior Trial in Boston, Philadelphia (Enhanced Usual Care (EOC), REVITALIZE ACT Intervention)

Active, not recruiting
  • Ovarian Cancer
  • +3 more
  • Enhanced Usual Care (EOC)
  • REVITALIZE ACT Intervention
  • Boston, Massachusetts
  • +1 more
Jun 13, 2022

Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY314, Combination Therapy: PY314 +

Recruiting
  • Advanced Solid Tumor
  • +8 more
  • PY314
  • Combination Therapy: PY314 + Pembrolizumab
  • Scottsdale, Arizona
  • +12 more
Mar 28, 2022

Advanced Solid Tumors, Head Neck Cancer, Pancreatic Cancer Trial in United States (Cabiralizumab, Nivolumab)

Completed
Has Results
  • Advanced Solid Tumors
  • +6 more
  • Cabiralizumab
  • Nivolumab
  • Scottsdale, Arizona
  • +38 more
Jan 5, 2022

Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma Trial in United States (CYT-0851, CYT-0851 in combination with gemcitabine,

Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
Mar 7, 2022

Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer Trial in Philadelphia, Dallas, Houston (ONM-100)

Completed
  • Breast Cancer
  • +6 more
  • Philadelphia, Pennsylvania
  • +2 more
Feb 9, 2022

Breast Cancer, Prostate Cancer, Ovarian Cancer Trial in Worldwide (Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib, Part 1,

Completed
  • Breast Cancer
  • +2 more
  • Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib
  • +3 more
  • San Marcos, California
  • +16 more
Jan 25, 2022